A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 20
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PsAID
Long Form : Psoriatic Arthritis Impact of Disease
No. Year Title Co-occurring Abbreviation
2020 Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. DAPSA, MDA, PASS, PsA, VLDA
2020 Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis. ASAS-HI, AUC, DAPSA, PsA
2020 Disease Activity in Psoriatic Arthritis Index and Psoriatic Arthritis Impact of Disease Questionnaire: correlation and sensitivity to change in a real clinical setting. DAPSA, PsA, SMR
2020 Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. DIP, HAQ, MDA, PsA
2020 Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. DAPSA, FM, HAQ-DI, MDA, PsA, PtGA, SCC
2020 Mismatch between the impact of disease perceived by patients and the state of clinical remission assessed by physicians in psoriatic arthritis. DAPSA, DAPSA, PASS, PsA
2020 Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. HRQoL, PsA
2020 Validation and clinical interpretability of PsAID - psoriatic arthritis impact of disease. CASPAR, EULAR, ICC, PsA
2019 A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. cDAPSA, HAQ, LDA, MDA, REM
10  2019 Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. DAPSA, MDA, NRS, OR, PsA
11  2019 Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). HRQoL, MCII, PASS
12  2019 Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. PARC, PRO, PsA, RAPID3
13  2019 Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis. CASPAR, DAPSA, VLDA
14  2018 Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. COSMIN, IDEOM, PG, PsA, RAPID, RCT
15  2018 Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. FACIT, GRAPPA, HAQ-DI, PsA, SPARCC
16  2018 Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab. MDA, OR, PsA, UST
17  2017 Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. ICC, PROM, PsA, SRM
18  2015 Patient global assessment in psoriatic arthritis - what does it mean? An analysis of 223patients from the Psoriatic arthritis impact of disease (PsAID) study. ---
19  2015 Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. EULAR, PROs
20  2014 A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. NRS, PsA